# Diagonal Therapeutics funding rounds and investors

As of 14 Oct 2026, Diagonal Therapeutics has raised $125M across 1 verified round on record; latest: $125 million Series B led by Janus Henderson Investors and Sanofi Ventures, announced 8 Jan 2026.

They develop innovative clustering antibodies for the treatment of genetic diseases.

Website: https://diagonaltx.com  
Page: https://fireround.dev/companies/diagonaltx.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-01-08 | Series B | $125 million | Janus Henderson Investors, Sanofi Ventures | Atlas Ventures, Balyasny Asset Management, Biovision Ventures, BVF Partners, Checkpoint Capital, Deep Track Capital, EcoR1 Capital, Frazier Life Sciences, Lightspeed, Logos Fund, RA Capital Management, RV Invest, Velosity Capital, Viking Global Investors, Woodline Partners | [vcaonline.com](https://www.vcaonline.com/news/2026010811/diagonal-therapeutics-announces-oversubscribed-125-million-series-b-financing-to-advance-clinical-development-of-disease-modifying-clustering-antibody-pipeline) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.